These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20698002)

  • 1. [Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents; a review of the literature and some recommendations'].
    Cohen D; de Hert M
    Tijdschr Psychiatr; 2010; 52(8):605-7; author reply 608. PubMed ID: 20698002
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations].
    Overbeek WA; de Vroede MA; Lahuis BE; Hillegers MH; de Graeff-Meeder ER
    Tijdschr Psychiatr; 2010; 52(5):311-20. PubMed ID: 20458678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents a review of the literature and some recommendations'].
    Roke Y
    Tijdschr Psychiatr; 2010; 52(7):535-6; discussion 536. PubMed ID: 20623452
    [No Abstract]   [Full Text] [Related]  

  • 4. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 5. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.
    de Leon J
    J Clin Psychopharmacol; 2008 Apr; 28(2):125-31. PubMed ID: 18344721
    [No Abstract]   [Full Text] [Related]  

  • 6. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
    Correll CU; Penzner JB; Parikh UH; Mughal T; Javed T; Carbon M; Malhotra AK
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):177-206. PubMed ID: 16321730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The metabolic syndrome and antipsychotics in children and adolescents].
    Dori N; Green T
    Harefuah; 2011 Oct; 150(10):791-6, 814, 813. PubMed ID: 22111125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.
    Eapen V; Shiers D; Curtis J
    Aust N Z J Psychiatry; 2013 May; 47(5):435-42. PubMed ID: 23047958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
    Parabiaghi A; Tettamanti M; D'Avanzo B; Barbato A;
    Acta Psychiatr Scand; 2016 Jan; 133(1):63-75. PubMed ID: 26252780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics.
    Centorrino F; Masters GA; Talamo A; Baldessarini RJ; Öngür D
    Hum Psychopharmacol; 2012 Sep; 27(5):521-6. PubMed ID: 22996619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
    Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
    Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pros and cons of antipsychotics in children and adolescents].
    Schmeck K
    Praxis (Bern 1994); 2015 Aug; 104(16):859-64. PubMed ID: 26242421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review on the current use of antipsychotic drugs in children and adolescents.
    Almandil NB; Wong IC
    Arch Dis Child Educ Pract Ed; 2011 Oct; 96(5):192-6. PubMed ID: 21771730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics in the treatment of children and adolescents.
    Findling RL
    J Clin Psychiatry; 2004; 65 Suppl 6():3-4. PubMed ID: 15104520
    [No Abstract]   [Full Text] [Related]  

  • 18. Haloperidol-Associated Uterine Dystonia.
    Ridout KK; Ridout SJ
    Am J Psychiatry; 2017 Mar; 174(3):296. PubMed ID: 28245696
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of antipsychotics in children and adolescents.
    Findling RL; Steiner H; Weller EB
    J Clin Psychiatry; 2005; 66 Suppl 7():29-40. PubMed ID: 16124839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic profile of haloperidol].
    Schiele B
    Acta Psiquiatr Psicol Am Lat; 1980 Mar; 26(1):72-6. PubMed ID: 6127873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.